PIPERACILLIN AND TAZOBACTAM

N/A

Manufactured by Apotex Corp.

21,987 FDA adverse event reports analyzed

Last updated: 2026-04-14

About PIPERACILLIN AND TAZOBACTAM

PIPERACILLIN AND TAZOBACTAM is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Apotex Corp.. The most commonly reported adverse reactions for PIPERACILLIN AND TAZOBACTAM include DRUG INEFFECTIVE, OFF LABEL USE, ACUTE KIDNEY INJURY, PYREXIA, THROMBOCYTOPENIA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for PIPERACILLIN AND TAZOBACTAM.

Top Adverse Reactions

DRUG INEFFECTIVE1,390 reports
OFF LABEL USE988 reports
ACUTE KIDNEY INJURY915 reports
PYREXIA869 reports
THROMBOCYTOPENIA470 reports
DRUG INTERACTION463 reports
PNEUMONIA450 reports
DIARRHOEA444 reports
CONDITION AGGRAVATED428 reports
SEPTIC SHOCK411 reports
HYPOTENSION403 reports
SEPSIS391 reports
DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS390 reports
DYSPNOEA386 reports
NEUTROPENIA371 reports
RASH356 reports
PRODUCT USE IN UNAPPROVED INDICATION347 reports
FEBRILE NEUTROPENIA332 reports
RESPIRATORY FAILURE327 reports
MULTIPLE ORGAN DYSFUNCTION SYNDROME292 reports
PANCYTOPENIA268 reports
VOMITING266 reports
NAUSEA247 reports
RASH MACULO PAPULAR235 reports
ANAEMIA234 reports
RENAL FAILURE234 reports
RENAL IMPAIRMENT226 reports
ABDOMINAL PAIN213 reports
EOSINOPHILIA200 reports
TOXIC EPIDERMAL NECROLYSIS199 reports
DEATH195 reports
PRURITUS193 reports
BLOOD CREATININE INCREASED187 reports
CARDIAC ARREST181 reports
TUBULOINTERSTITIAL NEPHRITIS180 reports
PLEURAL EFFUSION176 reports
CONFUSIONAL STATE175 reports
MALAISE173 reports
DRUG RESISTANCE171 reports
LEUKOPENIA168 reports
CLOSTRIDIUM DIFFICILE INFECTION161 reports
TOXICITY TO VARIOUS AGENTS159 reports
PATHOGEN RESISTANCE155 reports
TACHYCARDIA154 reports
HYPOXIA153 reports
COUGH151 reports
CHILLS150 reports
FATIGUE150 reports
INFECTION148 reports
CHOLESTASIS147 reports
DRUG INEFFECTIVE FOR UNAPPROVED INDICATION146 reports
GENERAL PHYSICAL HEALTH DETERIORATION145 reports
ASTHENIA142 reports
ACUTE RESPIRATORY DISTRESS SYNDROME141 reports
ERYTHEMA140 reports
RENAL TUBULAR NECROSIS139 reports
AGRANULOCYTOSIS138 reports
COVID 19138 reports
PAIN138 reports
ALANINE AMINOTRANSFERASE INCREASED136 reports
CLOSTRIDIUM DIFFICILE COLITIS136 reports
NEPHROPATHY TOXIC129 reports
PLATELET COUNT DECREASED129 reports
ENCEPHALOPATHY127 reports
HYPERSENSITIVITY127 reports
RENAL FAILURE ACUTE127 reports
STEVENS JOHNSON SYNDROME127 reports
CARDIAC FAILURE125 reports
METABOLIC ACIDOSIS123 reports
URINARY TRACT INFECTION123 reports
DRUG HYPERSENSITIVITY122 reports
HAEMOGLOBIN DECREASED122 reports
HYPERTENSION121 reports
TREATMENT FAILURE120 reports
ATRIAL FIBRILLATION119 reports
HYPOKALAEMIA118 reports
PRODUCT USE ISSUE118 reports
BRONCHOPULMONARY ASPERGILLOSIS116 reports
DECREASED APPETITE116 reports
DELIRIUM116 reports
HEPATIC ENZYME INCREASED113 reports
CANDIDA INFECTION112 reports
CYTOKINE RELEASE SYNDROME112 reports
INTERSTITIAL LUNG DISEASE112 reports
STAPHYLOCOCCAL INFECTION112 reports
DRUG INDUCED LIVER INJURY108 reports
HEPATIC FAILURE107 reports
LEUKOCYTOSIS107 reports
ASPARTATE AMINOTRANSFERASE INCREASED103 reports
GASTROINTESTINAL HAEMORRHAGE103 reports
ANAPHYLACTIC REACTION102 reports
CYTOMEGALOVIRUS INFECTION101 reports
HEPATIC FUNCTION ABNORMAL100 reports
DRUG LEVEL INCREASED97 reports
MUCOSAL INFLAMMATION96 reports
C REACTIVE PROTEIN INCREASED95 reports
ASPERGILLUS INFECTION94 reports
CIRCULATORY COLLAPSE93 reports
ACUTE GENERALISED EXANTHEMATOUS PUSTULOSIS92 reports
ACUTE RESPIRATORY FAILURE92 reports

Report Outcomes

Out of 12,109 classified reports for PIPERACILLIN AND TAZOBACTAM:

Serious 97.2%Non-Serious 2.8%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Male6,390 (58.5%)
Female4,505 (41.3%)
Unknown22 (0.2%)

Reports by Age

Age 63294 reports
Age 71271 reports
Age 74257 reports
Age 64242 reports
Age 58236 reports
Age 65235 reports
Age 61234 reports
Age 69221 reports
Age 70221 reports
Age 67219 reports
Age 66210 reports
Age 72205 reports
Age 68201 reports
Age 60200 reports
Age 62197 reports
Age 76195 reports
Age 73194 reports
Age 54186 reports
Age 56181 reports
Age 55180 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with PIPERACILLIN AND TAZOBACTAM?

This profile reflects 21,987 FDA FAERS reports that mention PIPERACILLIN AND TAZOBACTAM. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for PIPERACILLIN AND TAZOBACTAM?

Frequently reported terms in FAERS include DRUG INEFFECTIVE, OFF LABEL USE, ACUTE KIDNEY INJURY, PYREXIA, THROMBOCYTOPENIA, DRUG INTERACTION. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures PIPERACILLIN AND TAZOBACTAM?

Labeling and FAERS entries often list Apotex Corp. in connection with PIPERACILLIN AND TAZOBACTAM. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.